
813 patients enrolled
203 patients
Placebo
204 patients
AMG 108 – 50 mg
203 patients
AMG 108 – 125 mg
203 patients
AMG 108 – 250 mg
15 patients (7%) discontinued:
Protocol deviation: 2
Noncompliance: 1
Adverse event: 1
Withdrew consent: 7
Alternative therapy: 2
Lost to follow-up: 1
Other: 1
24 patients (12%) discontinued:
Protocol deviation: 1
Adverse event: 2
Withdrew consent: 13
Alternative therapy: 6
Lost to follow-up: 2
24 patients (12%) discontinued:
Protocol deviation: 3
Noncompliance: 1
Adverse event: 3
Withdrew consent: 11
Alternative therapy: 3
Lost to follow-up: 1
Other: 2
21 patients (10%) discontinued:
Protocol deviation: 2
Noncompliance: 2
Adverse event: 2
Withdrew consent: 7
Alternative therapy: 4
Lost to follow-up: 2
Other: 2
188 patients (93%) completed 24 weeks
180 patients (88%) completed 24 weeks
179 patients (88%) completed 24 weeks
182 patients (90%) completed 24 weeks